动物造模,异种移植 z-bio 2022-08-29 332

　　Objective: To establish a human-derived xenograft model of prostate cancer and evaluate the anti-tumor effect of different treatment regimens.

　　Methods: Fresh human prostate cancer surgical specimens were mixed with Matrigel and then transplanted into nude mice supplemented with exogenous androgens. Groups: docetaxel group, castration group, docetaxel combined castration group and control group, the tumor volume and the weight changes of mice were measured during the treatment, and after the treatment, the total prostate specific antigen (total prostate specific antigen) in serum was detected. specific antigen, tPSA) concentration and histopathological changes to evaluate the treatment effect.

　　Results: PDX models of prostate cancer were successfully established, including hormone-sensitive (D17225) and castration-resistant (C40019) tumors. Pathological analysis showed that the transplanted tumors kept the main characteristics of the primary tumor. Serum tPSA detection showed that the docetaxel group and the docetaxel combined with castration group showed good therapeutic effect in the D17225 model, and the latter had a more obvious tumor inhibition effect.

　　Conclusion: The prostate cancer PDX model was successfully established and stably passaged. Docetaxel alone or combined with castration treatment has a significant therapeutic effect on hormone-sensitive (D17225) prostate cancer PDX model.